This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

8 Stocks Rising on Unusual Volume

Questcor Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Questcor Pharmaceuticals (QCOR) is a biopharmaceutical company. Questcor's primary product is H.P. Acthar Gel (repository corticotropin injection) (Acthar), an injectable drug that is approved by the United States Food and Drug Administration, for the treatment of 19 indications. This stock is trading up 3.3% at $47.95 in recent trading.

Today's Volume: 1.6 million

Average Volume: 1.75 million

Volume % Change: 68%

Shares of QCOR are ripping higher today after the stock was upgraded by two different firms. Jefferies raised its target to $56 from $52 and reiterated its buy rating, while Oppenheimer upped its target to $59 from $53 and reiterated an outperform rating.

>>Stocks With Recent Analyst Upgrades

From a technical perspective, QCOR is moving notably higher here with decent volume. This move now has QCOR flirting with a major breakout trade, since the stock has briefly moved above some near-term overhead resistance at $48.98. At last check, QCOR has hit an intraday high of $49.13 and volume is very close to passing its three-month average action of 1.75 million shares.

Traders should now look for long-biased trades as long as QCOR is trending above $48.98 to $49.13 with strong upside volume flows. I would consider any upside volume day that registers near or above 1.75 million shares as bullish. If we get that action, then look for QCOR to tag $55 in the near future.

Also, keep in mind that a move above $49.13 will now mark an all-time high for QCOR, which is very bullish technical price action.

Questcor shows up on a recent list of Hot Biotech Stocks Traded by Hedge Funds.
6 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AIRM $35.81 -1.70%
ASIA $11.99 0.25%
COST $148.41 0.23%
QCOR $93.60 1.65%
AAPL $111.31 0.48%


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs